drugset / Trial / NCT06221969
A Research Study to See How Much CagriSema Lowers Blood Sugar and Body Weight Compared to Tirzepatide in People With Type 2 Diabetes Treated With Metformin With or Without an SGLT2 Inhibitor
RandomizedParallel-groupOpen-labelTreatment
Summary
This study will look at how well CagriSema helps people with type 2 diabetes lower their blood sugar and body weight. CagriSema is a new investigational medicine. Doctors may not yet prescribe CagriSema. CagriSema will be compared to a medicine called tirzepatide that doctors may prescribe in some countries. Participants will get either CagriSema or tirzepatide. Which treatment participant get is decided by chance like flipping a coin. Participant will have an equal chance of receiving either drug. For each participant, the study will last for up to one and a half years.
Timeline
- Start
- 2024-01-16
- Primary completion
- 2026-03-04
- Completion
- 2026-04-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cagrilintide | Protein / enzyme biologic | 2.4 mg | Subcutaneous |
| Subject | Semaglutide | Peptide | 2.4 mg | Subcutaneous |
| Comparator | Tirzepatide | Peptide | 15 mg | Subcutaneous |